Five Prime Therapeutics Stock News

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRX). The company's shares closed

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRX

Roth says cabiralizumab contributed $1 to Five Prime price target Roth Capital FPRX BMY

Five Prime Therapeutics (FPRX -4%) is down in early trade in response to its announcement that a Bristol-Myers Squibb-conducted Phase 2 clinical trial evaluating the combination of cabiralizumab and

Five Prime says cabiralizumab with Opdivo trial did not meet primary endpoint FPRX BMY

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer

Shares have fallen by 87% since my March article noted it was trading at lows with looming catalysts (a cautionary tale on trying to catch bottoms). Mark Lamper

Five Prime Therapeutics Inc (NASDAQ:FPRX) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,710,000 shares, a growth of 14.0% from the Jan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call

Cigna CEO David Cordani shared more details with investors about two upcoming partnerships for the company with Prime Therapeutics and Oscar Health.

Cigna CEO David Cordani said partnerships like its decision to sell new health plans with Oscar Health and its alliance with the pharmacy benefit manager Prime Therapeutics will escalate in 2020.

A look at the shareholders of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) can tell us which group is most powerful...

Gainers China Pharma Holdings, Inc. (NYSE: CPHI) shares climbed 96.5% to close at $0.92 on Monday after gaining 11.50% on Friday. Gulf Resources, Inc. (NASDAQ: GURE) shares...